Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High Following Better-Than-Expected Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares reached a new 52-week high on Wednesday following a better than expected earnings announcement. The stock traded as high as $23.10 and last traded at $24.3310, with a volume of 2640427 shares. The stock had previously closed at $20.46.

The company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the prior year, the business earned $0.69 EPS. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TEVA shares. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $25.86.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hara Capital LLC grew its holdings in Teva Pharmaceutical Industries by 4.7% in the first quarter. Hara Capital LLC now owns 31,814 shares of the company’s stock worth $489,000 after purchasing an additional 1,434 shares during the last quarter. Burford Brothers Inc. boosted its position in shares of Teva Pharmaceutical Industries by 2.1% in the 1st quarter. Burford Brothers Inc. now owns 155,876 shares of the company’s stock worth $2,396,000 after purchasing an additional 3,189 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 12.8% in the 1st quarter. Victory Capital Management Inc. now owns 3,410,142 shares of the company’s stock worth $52,414,000 after purchasing an additional 386,668 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in Teva Pharmaceutical Industries by 1.2% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock worth $404,775,000 after buying an additional 300,000 shares during the last quarter. Finally, Carnegie Lake Advisors LLC increased its position in Teva Pharmaceutical Industries by 23.8% during the 1st quarter. Carnegie Lake Advisors LLC now owns 85,350 shares of the company’s stock valued at $1,312,000 after buying an additional 16,400 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

The business has a 50 day simple moving average of $19.63 and a 200 day simple moving average of $17.76. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $27.53 billion, a PE ratio of -150.03, a PEG ratio of 1.11 and a beta of 0.70.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.